Ubs Asset Management Americas Inc Cytokinetics Inc Transaction History

Ubs Asset Management Americas Inc

$379 Billion
Q1 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 308,896 shares of CYTK stock, worth $9.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

308,896

Previous 315,250 2.02%

Holding current value

$9.58 Million

Previous $14.8 Million 16.29%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 19, 2025	SELL	$40.19 - $51.12 $255,367 - $324,816	-6,354 Reduced 2.02%	308,896 $12.4 Million
Q4 2024 Feb 14, 2025	BUY	$46.36 - $58.62 $2.25 Million - $2.84 Million	48,494 Added 18.18%	315,250 $14.8 Million
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $758,773 - $891,210	14,814 Added 5.88%	266,756 $14.1 Million
Q2 2024 Aug 13, 2024	BUY	$47.86 - $75.05 $6.41 Million - $10.1 Million	134,020 Added 113.65%	251,942 $13.7 Million
Q1 2024 May 15, 2024	BUY	$63.75 - $108.06 $86,508 - $146,637	1,357 Added 1.16%	117,922 $8.27 Million
Q4 2023 Feb 14, 2024	SELL	$26.88 - $83.49 $115,019 - $357,253	-4,279 Reduced 3.54%	116,565 $9.73 Million
Q3 2023 Nov 13, 2023	BUY	$29.46 - $36.61 $156,079 - $193,959	5,298 Added 4.59%	120,844 $3.56 Million
Q1 2023 May 15, 2023	BUY	$33.36 - $45.71 $608,953 - $834,390	18,254 Added 18.76%	115,546 $4.07 Million
Q4 2022 Feb 14, 2023	BUY	$35.77 - $51.11 $554,900 - $792,869	15,513 Added 18.97%	97,292 $4.46 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $681,040 - $963,422	-17,671 Reduced 17.77%	81,779 $3.96 Million
Q2 2022 Aug 12, 2022	BUY	$33.93 - $48.92 $197,031 - $284,078	5,807 Added 6.2%	99,450 $3.91 Million
Q1 2022 May 16, 2022	SELL	$29.74 - $46.0 $15,613 - $24,150	-525 Reduced 0.56%	93,643 $3.45 Million
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $850,437 - $1.15 Million	24,758 Added 35.67%	94,168 $4.29 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $120,046 - $231,416	6,475 Added 10.29%	69,410 $2.48 Million
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $9,538 - $13,009	-482 Reduced 0.76%	62,935 $1.25 Million
Q1 2021 May 14, 2021	BUY	$18.57 - $25.68 $182,765 - $252,742	9,842 Added 18.37%	63,417 $1.48 Million
Q4 2020 Mar 01, 2021	BUY	$15.26 - $28.61 $9,873 - $18,510	647 Added 1.22%	53,575 $1.11 Million
Q3 2020 Nov 13, 2020	BUY	$20.58 - $28.96 $93,001 - $130,870	4,519 Added 9.34%	52,928 $1.15 Million
Q2 2020 Aug 14, 2020	SELL	$11.15 - $24.64 $122,114 - $269,857	-10,952 Reduced 18.45%	48,409 $1.14 Million
Q1 2020 May 15, 2020	BUY	$8.75 - $16.3 $110,950 - $206,684	12,680 Added 27.16%	59,361 $699,000
Q4 2019 Feb 14, 2020	SELL	$7.95 - $11.84 $89,763 - $133,685	-11,291 Reduced 19.48%	46,681 $495,000
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $313,217 - $412,509	28,948 Added 99.74%	57,972 $659,000
Q1 2019 May 14, 2019	BUY	$5.95 - $10.19 $16,802 - $28,776	2,824 Added 10.78%	29,024 $0
Q2 2018 Aug 14, 2018	BUY	$6.9 - $9.9 $180,780 - $259,380	26,200 New	26,200 $0

Others Institutions Holding CYTK

# of Institutions

408

Shares Held

127M

Call Options Held

3.66M

Put Options Held

900K

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $2.92B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Cytokinetics Inc Transaction History